STAT

The coronavirus is washing over the U.S. These factors will determine how bad it gets in each community

As the #coronavirus outbreak rolls across the country, residents are asking: Who will be hit next? And how fast and how hard? These are the factors that determine the answers.

On March 15, the governor of Washington called the Seattle area the “hotbed of this outbreak.”

“Code Red,” blared the tabloid cover of the New York Post eight days later.

And this weekend, the Tampa Bay Times forecast that Florida, where the governor has not imposed statewide stay-at-home measures, would “see tens of thousands of infections in the coming weeks” from the coronavirus pandemic.

Two months after the first case of Covid-19 was confirmed in the United States, the virus has sprung from its initial toeholds and started to shift the country’s infection map — from one of pockmarked hotspots to one that blankets the entire nation. Detroit. New Orleans. Dallas. These are among the cities that could be the next hubs of the U.S. emergency, and where the virus has likely been spreading for weeks.

As the outbreak rolls across the country, residents are asking: Who will be hit next? And how fast and how hard?

“It’s very feasible we’re going to see multiple city- or state-level outbreaks across the country in the next few weeks and months,” said Maia Majumder, a computational epidemiologist at Boston Children’s Hospital. “They will start at different times and they will peak at different times.”

Experts told STAT that a host of factors are at play: demographics like

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Cigna Biosimilar Plans, A Vertex Deal In South Africa, And More
Cigna plans to make copies of AbbVie's Humira arthritis drug available with no out-of-pocket payment to eligible patients in the U.S.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Biocon Eyeing Weight Loss Drugs, Sanofi Layoffs, And More
Biocon is pivoting to weight loss drugs as patents for the blockbuster medicines start to expire, unleashing a coming wave of generics.

Related Books & Audiobooks